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Induction of complex immune responses 
and strong protection against retrovirus 
challenge by adenovirus-based immunization 
depends on the order of vaccine delivery
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Abstract 
Background: In the Friend retrovirus mouse model we developed potent adenovirus-based vaccines that were 
designed to induce either strong Friend virus GagL85–93-specific CD8
+ T cell or antibody responses, respectively. To 
optimize the immunization outcome we evaluated vaccination strategies using combinations of these vaccines.
Results: While the vaccines on their own confer strong protection from a subsequent Friend virus challenge, the 
simple combination of the vaccines for the establishment of an optimized immunization protocol did not result in 
a further improvement of vaccine effectivity. We demonstrate that the co-immunization with GagL85–93/leader-gag 
encoding vectors together with envelope-encoding vectors abrogates the induction of GagL85–93-specific CD8
+ T 
cells, and in successive immunization protocols the immunization with the GagL85–93/leader-gag encoding vector 
had to precede the immunization with an envelope encoding vector for the efficient induction of GagL85–93-specific 
CD8+ T cells. Importantly, the antibody response to envelope was in fact enhanced when the mice were adenovirus-
experienced from a prior immunization, highlighting the expedience of this approach.
Conclusions: To circumvent the immunosuppressive effect of envelope on immune responses to simultaneously 
or subsequently administered immunogens, we developed a two immunizations-based vaccination protocol that 
induces strong immune responses and confers robust protection of highly Friend virus-susceptible mice from a lethal 
Friend virus challenge.
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Background
The development of an effective HIV vaccine has been a 
priority in retrovirus research since the early days of its 
discovery more than 30  years ago. Innumerable vector-
based vaccine approaches have been developed in pre-
clinical models, and many vaccine candidates have been 
tested in clinical trials, some of them in large phase IIb 
and III trials. However, in the first efficacy trials hopes 
were dashed because a protein-based vaccine, although 
immunogenic, proved completely ineffective [1], and an 
adenovirus-based vaccine did not result in either pro-
tection or reduction of setpoint viral loads and was even 
associated with an increased HIV infection rate in Ad5 
pre-immune, uncircumcised male vaccinees [2, 3]. More 
encouraging results were obtained in the Thai trial, where 
a combination of vaccinia-based vectors and the previ-
ously phase III-tested protein vaccine conferred modest 
protection in a low-risk cohort [4]. The development of a 
potent HIV vaccine is complicated by the lack of a good 
animal model; the only animal models that support rep-
lication of HIV are humanized mice [5] and chimpanzees 
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[6], but the humanized mouse models to date are not very 
suitable for immunization studies [7]. Therefore, most 
experimental vaccine studies are carried out in macaques 
using the related simian immunodeficiency virus (SIV) 
infection, or as more basic studies in mice, immunizing 
against HIV proteins without the option of a challenge 
infection, or working with simple mouse retroviruses. 
From studies in these animal models, it has been found 
that only attenuated virus confers truly sterile protec-
tion [8–11], but the use of an attenuated HIV for human 
immunization is regarded by most as too hazardous [12–
15]. From experiments performed in the mouse model it 
could be demonstrated that a complex immune response 
consisting of CD4+ and CD8+ T cell and antibody 
responses is required for complete protection [10, 16].
From studies of human HIV infection and of SIV infec-
tion of non-human primates it has been recognized that 
sterile protection must be achieved to prevent seeding 
into reservoirs such as latently infected CD4+ T cells or 
immunologically privileged sites, which happens rapidly 
after infection [17, 18]. It has been demonstrated that an 
important reservoir are follicular helper CD4+ T cells 
which reside in the immunologically privileged B cell fol-
licle of the lymph nodes where the virus escapes elimi-
nation by CD8+ T cells [19, 20]. To prevent reservoir 
seeding, the vaccine-induced immune response, there-
fore, would have to be very swift; the only vaccine which 
has been shown to eliminate any detectable virus from 
reservoirs in the SIV model is a rhesus cytomegalovirus-
based vaccine [21, 22] that has been shown to protect via 
unconventional T cell responses [23, 24].
For the improvement and optimization of adenovirus-
based immunization strategies we employ the Friend 
virus (FV) infection of mice as a retroviral infection 
model. FV is an immunosuppressive retrovirus complex 
consisting of the Friend murine leukemia virus (F-MuLV) 
and the replication-defective, pathogenic Friend spleen 
focus forming virus [25]. The polycythemic FV com-
plex induces the rapid development of splenomegaly 
and lethal erythroleukemia in susceptible adult mice, 
making the FV infection of these mice a very stringent 
model for vaccine testing, as we have described before 
[26]. Experiments in the FV model allowed us to develop 
different strategies to improve the adenovirus-based 
anti-retroviral immunization. We have reported on the 
expression-display adenovirus vector design where the 
vaccine immunogen is not only encoded by the adeno-
viral vector but also displayed on the adenovirus cap-
sid [27] and the use of select genetic adjuvants such as 
type I interferons, chemokines and interleukins [28–30] 
for the induction of improved antibody and CD4+ T cell 
responses. We could also demonstrate the necessity for 
immunogen modification to allow for the induction of 
FV-specific CD8+ T cells by adenovirus-based immu-
nization [31]. The immunization of highly FV-suscepti-
ble mice with these advanced vaccines results in a high 
degree of protection, with strongly reduced viral loads 
and protection from FV-induced disease.
Many vaccines have been described before for the 
immunization against FV, the vaccines tested include 
attenuated N-tropic F-MuLV-N or FV-N [10, 16, 32, 33], 
replication-defective [34] or inactivated F-MuLV [35], 
protein [36, 37] and peptide vaccines [38–40], cell-based 
vaccines such as FV-derived tumor cells [33] or F-MuLV- 
or peptide-loaded dendritic cells [41], nano-particle-
based vaccines [42], or gene-based vaccines such as 
DNA-based vectors [43], vaccinia-based vectors [44–46], 
or the adenovirus-based vectors developed by us [26–
31]. While comparisons are sometimes difficult due to 
the different mouse strains and widely differing FV chal-
lenge doses that were employed in the various studies, it 
has to be noted that until now, only the immunization 
with attenuated F-MuLV conferred complete protection 
to FV-susceptible mice.
We describe here our approaches to an optimized com-
bination of our adenovirus-based vaccines for immuniza-
tion of highly FV-susceptible mice. In order to reach the 
most extensive immunity, the individual vaccines had to 
be combined in one immunization regimen to induce 
all required arms of immunity. Our results show that 
the order of administration of the individual vaccines is 
crucial for the vaccination outcome, as the GagL85–93- 
specific CD8+ T cell response was greatly diminished 
if GagL85–93/leader-gag encoding vectors were applied 
together with, or following, env encoding vectors, and the 
antibody response to an Ad vector delivered immunogen 
was actually enhanced in adenovirus-experienced mice. 
We demonstrate that a combination of adenovirus-based 
vaccines in an optimal vaccination scheme can mediate 
protection that is comparable to that mediated by a live 
attenuated Friend murine leukemia virus.
Methods
Cells and cell culture
The human embryonic kidney cell line 293 (Microbix 
Biosystems, Toronto, ON, Canada) was propagated in 
Dulbecco’s modified Eagle medium (DMEM) with high 
glucose. A murine fibroblast cell line from Mus dunni 
[47] and the murine hybridoma cell lines 720 [48] and 
TC31-9C12.C9 [49] (Developmental Studies Hybridoma 
Bank, IA) were maintained in RPMI medium (Invitrogen/
Gibco, Karlsruhe, Germany). Cell culture media were 
supplemented with 10% heat-inactivated fetal bovine 
serum (Invitrogen/Gibco) and 50 µg/ml gentamicin. Cell 
lines were maintained in a humidified 5% CO2 atmos-
phere at 37 °C.
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Adenovirus‑based and attenuated retrovirus vaccines
The following vectors have been described before: Ad5.
env [26] encodes full-length F-MuLV Env. Ad5.pIXgp70 
[27] encodes a fusion protein of the adenovirus capsid 
protein pIX and F-MuLV Env gp70. Ad5.leader-gag [26] 
encodes full-length F-MuLV leader-gag protein. Ad5.
TxnGagL [31] encodes a fusion protein of the murine 
cellular protein thioredoxin and the immunodominant 
F-MuLV CD8+ T cell epitope GagL85–93. Ad5.GagC1K 
[31] encodes full-length F-MuLV leader-gag protein with 
a Y94K mutation. All F-MuLV sequences in the vaccine 
vectors have been derived from F-MuLV clone FB29 [50]. 
Ad5.GFP [51] encodes enhanced green fluorescent pro-
tein from Aequorea victoria. Ad5.ova encodes chicken 
egg ovalbumin and has originally been published Ad5-
ΔGM-OVA [52].
Ad5.empty does not contain any transgenic sequences 
and was obtained by homologous recombination of 
pShuttle-CMV with pAdEasy-1 and transfection into 293 
cells as described before [53].
All adenoviral vectors were purified with the Vivapure 
AdenoPACK 100 kit (Vivascience, Hannover, Germany). 
The adenovirus particle concentrations were determined 
by spectrophotometry as described previously [54] and 
calculated as viral particles (vp)/ml. The particle-to-PFU 
ratio of all vector preparations was ~30:1.
The N-tropic Friend murine leukemia virus (F-MuLV-
N) was cultivated on the Mus dunni fibroblast cell line 
and obtained from cell culture supernatant of infected 
cells.
Mice
Female CB6F1 hybrid mice (BALB/c x C57BL/6 F1; 
H-2b/d Fv1b/b Fv2r/s Rfv3r/s) and female BALB/c mice were 
purchased from Charles River Laboratories (Sulzfeld, 
Germany). All mice were used when they were between 8 
and 9 weeks of age.
Immunization
CB6F1 mice were immunized with 109 vp of the respec-
tive adenovirus vaccines subcutaneously into the hind 
footpads in 50  µl PBS, or intramuscularly in 30  µl PBS. 
Both administration routes lead to comparable results 
in our hands (unpublished observation). The amount of 
virus particles in all groups was maintained equal when 
some groups received more than one transgene-encoding 
vector by adding the appropriate amount of empty vector 
Ad5.empty as needed. When mice were immunized more 
than once, the immunizations were performed in a three 
week interval.
Immunization with the attenuated F-MuLV-N was per-
formed by intravenous injection of 10,000 focus forming 
units in 100 µl PBS.
FV and challenge infection
Uncloned, lactate dehydrogenase-elevating virus (LDV)-
free FV stock was obtained from BALB/c mouse spleen 
cell homogenate (10%, wt/vol) 14 days post infection with 
a B cell-tropic, polycythemia-inducing FV complex [55]. 
CB6F1 mice were challenged by the intravenous injection 
of 5000 spleen focus-forming units.
Viremia assay
Ten days post challenge (p.c.), plasma samples from 
CB6F1 mice were obtained, and viremia was determined 
in a focal infectivity assay [56]. Serial dilutions of plasma 
were incubated with M. dunni cells for 3  days under 
standard tissue culture conditions. When cells reached 
~100% confluence, they were fixed with ethanol, labeled 
with F-MuLV Env-specific MAb 720 [48], and then with 
a horseradish peroxidase (HRP)-conjugated rabbit anti-
mouse Ig antibody (Dako, Hamburg, Germany). The 
assay was developed using aminoethylcarbazole (Sigma-
Aldrich, Deisenhofen, Germany) as substrate to detect 
foci. Foci were counted, and focus-forming units (FFU)/
ml plasma were calculated.
Infectious center assay
21  days p.c., animals were sacrificed by cervical dis-
location, the spleens were removed and weighed, and 
single-cell suspensions were prepared. Serial dilu-
tions of isolated spleen cells were seeded onto M. dunni 
cells, and cells were incubated under standard tissue 
culture conditions for 3  days, fixed with ethanol, and 
stained as described for the viremia assay. Resulting foci 
were counted, and infectious centers (IC)/spleen were 
calculated.
Binding antibody ELISA
For the analysis of F-MuLV-binding antibodies, Max-
iSorp ELISA plates (Nunc, Roskilde, Denmark) were 
coated with whole F-MuLV antigen (5  µg/ml); for the 
analysis of adenovirus-binding antibodies, plates were 
coated with 5  µg/ml Ad5.empty. After coating, plates 
were blocked with 10% fetal calf serum in PBS, and incu-
bated with serum dilutions. Binding antibodies were 
detected using a polyclonal rabbit-anti-mouse HRP-
coupled anti-IgG antibody and the substrate tetrameth-
ylbenzidine (TMB+; both Dako Deutschland GmbH, 
Hamburg, Germany). Sera were considered positive if the 
optical density at 450 nm was threefold higher than that 
obtained with sera from naïve mice.
Complement‑dependent F‑MuLV‑neutralizing antibody 
assay
To detect F-MuLV-neutralizing antibodies, serial dilu-
tions of heat-inactivated plasma in PBS were mixed with 
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purified F-MuLV and guinea pig complement (Sigma 
Aldrich, Munich, Germany), incubated at 37  °C for 
60 min, and then added to M. dunni cells that had been 
plated at a density of 7.5 × 103 cells per well in 24-well 
plates the day before. Seventy-two hours later cells were 
stained as described for the viremia assay. Dilutions that 
resulted in a reduction of foci by 90% or more were con-
sidered neutralizing.
Tetramer staining of F‑MuLV‑specific CD4+ T cells
F-MuLV-specific CD4+ T cells were analyzed in periph-
eral blood cells two weeks after immunization or 10 days 
p.c., or in spleen cells three days p.c.; erythrocytes were 
lysed before the staining when blood samples were used. 
Cells were stained with an allophycocyanin (APC)-coupled 
major histocompatibility complex (MHC) class II tetramer 
(containing the I-Ab-restricted F-MuLV Env123–141 
epitope EPLTSLTPRCNTAWNRLKL [57]; kindly pro-
vided by the MHC Tetramer Core Facility of the National 
Institutes of Health, National Institute of Allergy and 
Infectious Diseases, Atlanta, GA), fluorescein isothiocy-
anate (FITC)–anti-CD11b, peridinin chlorophyll protein 
(PerCP)–anti-CD43, Brilliant Violet (BV) 510-anti-CD44, 
BV605-anti-CD4 (Becton–Dickinson, Heidelberg, Ger-
many) and Fixable Viability Dye eFluor 780 (eBioscience, 
Frankfurt, Germany). Data were acquired on an LSR II flow 
cytometer (Becton–Dickinson, Mountanview, CA) and 
analyzed using FlowJo software (Tree Star, Ashton, OR).
Tetramer staining of F‑MuLV‑specific CD8+ T cells
F-MuLV-specific CD8+ T cells were analyzed in periph-
eral blood two weeks after immunization, or 10  days 
p.c. After lysis of erythrocytes, blood cells were stained 
with PE-coupled MHC I tetramer (containing the H-2Db 
restricted F-MuLV Gag-leader epitope AbuAbulLAb-
uLTVFL in which cysteine residues of the original amino 
acid sequence GagL85–93 (CCLCLTVFL) were replaced 
by amino-butyric acid (Abu) to prevent disulfide bond-
ing [58]; MBL, Woburn, MA), PerCP-anti-CD43, 
eFluor450-anti-CD8, BV510-anti-CD44 (Becton–Dick-
inson, Heidelberg, Germany) and Fixable Viability Dye 
eFluor 780 (eBioscience, Frankfurt, Germany). Data were 
acquired on an LSR II flow cytometer (Becton–Dickin-
son, Mountanview, CA) and analyzed using FlowJo soft-
ware (Tree Star, Ashton, OR).
Flow‑cytometric analysis of regulatory T cells
Regulatory T cells were analyzed in popliteal and ingui-
nal lymph nodes draining the site of intramuscular 
vaccine administration two weeks after the immu-
nization. Lymph node cells were stained with anti-
bodies AlexaFluor680-anti-CD4, FITC-anti-CD44, 
PE-anti-CD103, PeCy7-anti-CD62L, APC-anti-KLRG1 
(Becton–Dickinson, Heidelberg, Germany) and Fix-
able Viability Dye eFluor 780 (eBioscience, Frankfurt, 
Germany); after fixation with FoxP3/transcription fac-
tor fixation/permeabilization kit (eBioscience, Frank-
furt, Germany) cells were stained intracellularly with 
eFluor450-anti-FoxP3 (Becton–Dickinson, Heidelberg, 
Germany). Data were acquired on an LSR II flow cytome-
ter (Becton–Dickinson, Mountanview, CA) and analyzed 
using FlowJo software (Tree Star, Ashton, OR).
Intracellular cytokine staining
For the analysis of effector molecules of immunogen- or 
vector-specific CD8+ T cells, blood samples were col-
lected and subjected to erythrocyte lysis. Cells were 
stimulated for 6 h in vitro with 2 µg/ml ova257–264 peptide 
(SIINFEKL), 1  µg/ml Abu-modified GagL85–93 peptide 
(AbuAbuLAbuLTVFL; Abu-modified from the original 
sequence CCLCLTVFL), or 10  µg/ml Ad5 Hexon486–494 
(KSYPSNVKI) and DBP418–426 (FALSNAEDL) [59] in the 
presence of 2 µg/ml brefeldin A. Cells were stained with 
eFluor450-anti-CD8, PerCP-anti-CD43, BV510-anti-
CD44, FITC-anti-interferon γ (IFNγ), PE-anti-interleukin 
2 and APC-Cy7-anti-tumor necrosis factor α (TNFα; 
Becton–Dickinson, Heidelberg, Germany).
For the analysis of effector molecules of F-MuLV Env-
specific CD4+ T cells, blood samples were collected and 
subjected to erythrocyte lysis; then cells were stimulated 
in vitro for 72 h with 10 µg/ml of the peptides Env57–71 
(ETVWAISGNHPLWTW), Env91–105 (GLEYRAPYSSP-
PGPP), Env415–430 (KGSYYLVAPAGTMWAC), Env267–281 
(PRVPIGPNPVLADQL), Env277–291 (LADQLSFPLPN-
PLPK) [60] and Env123–141 (EPLTSLTPRCNTAWNRLKL) 
in the presence of 10 units/ml human interleukin 2 
(IL2) (Roche Diagnostics, Mannheim, Germany). Cells 
were then restimulated with the above peptides in the 
presence of 10 units/ml human interleukin 2 and 2  µg/
ml brefeldin A for an additional 6  h. Cells were stained 
with BV605-anti-CD4, BV510-anti-CD44, FITC-anti-
IFNγ, PE-anti-IL2, PE-Cy7-anti-IL4, APC-anti-IL21, and 
BV421-anti-IL10.
All data were acquired on an LSR II flow cytometer 
(Becton–Dickinson, Mountanview, CA) and analyzed 
using FlowJo software (Tree Star, Ashton, OR).
Transfer of cells and plasma
For the transfer of CD4+ T cells, single cell suspensions 
were prepared from lymph nodes and spleens, and CD4+ 
T cells were isolated by magnetic bead labelling using 
a CD4+ T cell isolation kit (Miltenyi Biotec, Bergisch-
Gladbach, Germany). Successful cell separation was con-
firmed by flow cytometry, and 107 CD4+ cells in 200 µl 
PBS containing 3 units heparin were injected intrave-
nously into recipient mice.
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For the transfer of plasma, blood was collected and 
immediately mixed with 1.5 units heparin/100  µl, and 
blood cells were removed by centrifugation at 1000g for 
10 min. After verification of the anti-adenovirus antibody 
titer by ELISA, 200 µl plasma were injected intravenously 
into recipient mice.
To obtain antibody-free plasma, samples were collected 
as described above, and incubated repeatedly with pro-
tein G-Sepharose beads (GE Healthcare Life Sciences, 
Freiburg, Germany). Removal of any detectable adeno-
virus-specific antibodies was confirmed by ELISA. Mice 
received an equal amount, i.e. 200  µl, of the antibody-
cleared plasma.
Statistical analyses
Statistical analyses were performed using the software 
SigmaStat 3.1 (Systat Software GmbH, Erkrath, Ger-
many), testing with the Mann–Whitney Rank Sum test 
or Student’s t-test for the comparison of two groups or 
the Kruskal–Wallis one-way analysis of variance on ranks 
and Student–Newman–Keuls (equally sized groups) or 
Dunn’s (unequally sized groups) multiple comparison 
procedure for the comparison of three or more groups. 
Analysis of statistical power was performed using the 
software GPower3.1 [61].
Results
Combination of Env and Gag encoding vectors results 
in loss of GagL85–93‑specific CD8
+ T cell responses
We have described before that vaccination with the vac-
cines Ad.TxnGagL or Ad.GagC1K induce strong CD8+ T 
cell responses to the immunodominant F-MuLV CD8+ 
T cell epitope GagL85–93 and induces a high degree of 
protection in highly FV-susceptible mice [31]. On the 
other hand, we have developed vectors and vaccine com-
binations that confer similarly strong protection by the 
induction of F-MuLV-specific antibodies and CD4+ T 
cells [27–30]. While the immune protection conferred by 
these different vaccines is very good and protects highly 
susceptible mice from FV-induced disease, protection is 
not complete and most mice still harbor virus, albeit at 
low levels.
To further increase the effectivity of our adenovirus-
based vaccination regimen, we combined the two CD8+ 
T cell inducing vaccines Ad.TxnGagL and Ad.GagC1K 
with the expression-display vector Ad.pIXgp70, which 
encodes and displays a fusion protein of the adenovirus 
capsid protein pIX and the F-MuLV envelope gp70 and 
induces strong antibody and CD4+ T cell responses. 
CB6F1 mice were immunized twice with Ad.TxnGagL 
or Ad.GagC1K alone or in combination with Ad.pIXgp70, 
and two weeks after the second immunization the 
GagL85–93-specific CD8+ T cell response was analyzed 
by MHC I tetramer staining. Mice that were immunized 
with Ad.TxnGagL or Ad.GagC1K alone mounted a GagL85–
93-specific CD8+ T cell response that, while higher in the 
Ad.TxnGagL group as seen and reported before [31], 
was easily detectable in both groups; co-immunization 
with Ad.pIXgp70 however led to a significant reduction 
of the GagL85–93-specific CD8+ T cell response (Fig. 1a; 
P < 0.05). Accordingly, when the viral loads in spleens of 
mice three weeks after an FV challenge infection were 
analyzed, we found no improved protection in the mice 
that were immunized with the vaccine combinations 
(Fig. 1b).
The dampening effect of the F-MuLV envelope on 
the response to other immunogens is not exclusively 
observed with other retroviral proteins but could also be 
demonstrated when mice were immunized with an oval-
bumin encoding adenoviral vector, where we found the 
CD8+ T cell response to the ovalbumin epitope ova257–264 
significantly reduced by co-adminstration of Ad.Env 
(Additional file 1; P < 0.05).
This reduction of CD8+ T cell responses by the co-
administration of Ad.Env suggested that immunodomi-
nance effects might be at play, therefore we analyzed if 
the abrogation of the CD8+ T cell induction was depend-
ent on colocalization of the two vaccines. We immunized 
mice with Ad.GagC1K and Ad.pIXgp70 and applied the 
two vaccines either as a mixture, or separately, one into 
each hind leg. The CD8+ T cell response to GagL85–93 was 
again analyzed by MHC I tetramer staining two weeks 
after immunization, and it was apparent that both groups 
immunized with the two vectors had failed to mount an 
appropriate GagL85–93-specific CD8+ T cell response, 
in stark contrast to the control group that received the 
Ad.GagC1K vaccine alone (Fig. 1c; P < 0.05). Interestingly, 
the protection conferred to all three groups was equally 
strong, and many animals had undetectable viral loads 
(Fig. 1d).
The order of vaccine administrations is crucial for the 
induction of CD8+ T cells
As the spatial separation of the two vaccines did not 
result in the induction of CD8+ T cells, we immunized 
mice once with Ad.TxnGagL and Ad.pIXgp70, one vac-
cine at a time, using either Ad.TxnGagL or Ad.pIXgp70 
first, followed three weeks later by the other vaccine (see 
Additional file 2 for the vaccination scheme). When the 
GagL85–93-specific CD8+ T cell response was analyzed 
two weeks after the second immunization, we found an 
expectedly high frequency of GagL85–93-specific CD8+ 
T cells in mice that had received only one immunization 
with Ad.TxnGagL, and also the control group that had 
received a GFP-encoding vector as the first immuniza-
tion showed an equally high GagL85–93-specific CD8+ T 
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cell response (Fig. 2a). However, mice that had received 
Ad.pIXgp70 as the first vaccine followed by Ad.TxnGagL 
mounted a gravely reduced GagL85–93-specific CD8+ 
T cell response (P  <  0.05). Mice that had received 
Ad.TxnGagL first, followed by Ad.pIXgp70, showed a 
GagL85–93-specific CD8+ T cell response that was compa-
rable to that seen in mice immunized with Ad.TxnGagL 
alone, demonstrating that the subsequent immuniza-
tion with Ad.pIXgp70 did not abrogate the CD8+ T cell 
response induced by the first immunization. Interestingly, 
this also demonstrates that the GagL85–93-specific CD8+ 
T cell population had not contracted noticeably at this 
time point five weeks after the immunization.
To analyze the GagL85–93-specific CD8+ T cell response 
in more detail, we restimulated cells from immunized 
mice with GagL85–93 peptide and subjected them to 
intracellular cytokine staining (Additional file  3). Stim-
ulation of cells from unvaccinated mice resulted in a 
low background staining for IFNγ, TNFα and IL2; cells 






























































































































































































Fig. 1 Induction of GagL85–93-specific CD8
+ T cell responses by combined Ad-based vaccines. a, b CB6F1 mice were immunized twice in a 3-week 
interval by subcutaneous injection with 109 vp of the indicated vaccines, the groups that received only one transgene-encoding vector received 
an equal amount of Ad.empty. Vaccines were mixed and injected into both hind footpads. c, d CB6F1 mice were immunized twice in a three-week 
interval by subcutaneous injection of 109 vp of the indicated vaccines, the two vaccines Ad.GagC1K and Ad.pIXgp70 were either mixed and injected 
into both hind footpads (“mixed”), or the two vaccines were kept separate and injected into one footpad each (“left/right”). GagL85–93-specific 
CD8+ T cell responses were analyzed in peripheral blood samples two weeks after the second immunization (a, c). Three weeks after the second 
immunization, mice were infected with FV, and the viral load in spleens was analyzed three weeks after the FV challenge (b, d). The data shown 
were obtained in two independent experiments. Each dot represents one mouse, lines indicate mean (a, c) or median (b, d) values, dashed lines 
indicate the limit of detection. Data were analyzed by Kruskall–Wallis One Way Analysis of Variance on Ranks and Student–Newman–Keuls multiple 
comparison procedure; significant differences (P < 0.05) compared to unvaccinated mice are indicated by *, significant differences compared to 
mice vaccinated with the respective single vaccine are indicated by #. Sufficient statistical power was verified [SP = 0.89 (a), 1.0 (b), 0.89 (c), 0.99 (d)]
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by Ad.TxnGagL gave a similar picture yet with a very 
small population of cells producing two cytokines. On 
the other hand, if mice received Ad.TxnGagL either as a 
single immunization or as the first vaccine followed by 
Ad.pIXgp70, the frequency of cytokine-producing cells 
was strongly increased with almost half of the cells pro-
ducing more than one cytokine.
Three weeks after the completed immunization, mice 
were challenged with Friend virus, and ten days later 
blood samples were collected for the analysis of viral 
loads and of CD4+ and CD8+ T cell responses. The MHC 
I tetramer staining showed the same trends as observed 
before the challenge infection, with a still severely 
impaired GagL85–93-specific CD8+ T cell response 
in the mice immunized with Ad.pIXg70 followed by 
Ad.TxnGagL, which was comparable to that observed 
in unvaccinated mice, demonstrating that there was 
no rapid anamnestic proliferation of vaccine-induced 
GagL85–93-specific CD8+ T cells (Fig.  2b). The MHC 
II tetramer staining showed no significant differences 
between the vaccinated groups at this time point (Fig. 2c). 
The mice that mounted strong GagL85–93-specific CD8+ 
T cell responses showed a strong reduction in viral loads 
in the plasma on day 10 and in the spleens on day 21 after 
FV challenge infection (Fig. 2d, e); mice that were immu-
nized with Ad.pIXgp70 followed by Ad.TxnGagL had 
mostly very high viral loads. The mice that had received 
a single immunization with Ad.pIXgp70 had similarly 
high viral loads that were not significantly lower than 
in unvaccinated mice, however, if mice had received an 
injection of the control vector Ad.GFP before the immu-
nization with Ad.pIXgp70, they surprisingly showed a 
very strong protection from FV infection, with undetect-
able viremia and very low, if detectable, spleen viral load. 
As we had not seen significant differences in the cellular 
immune responses of mice immunized with Ad.pIXgp70 
with or without a prior immunization with Ad.GFP 
(Fig.  2b, c), we analyzed F-MuLV-binding antibodies in 
serum samples collected two weeks after the Ad.pIXgp70 
immunization (Fig. 2f ). While all but one mice that had 
received a single injection of Ad.pIXgp70 without prior 
immunization failed to mount detectable antibodies at 
this time point, mice that had been injected with Ad.GFP 
before receiving Ad.pIXgp70 had a significantly higher 
binding antibody response (P < 0.05).
To further characterize the suppressive effect of 
Ad.pIXgp70 on the subsequent Ad.TxnGagL immuni-
zation, we investigated if the effect would persist over a 
longer time period. Therefore, mice were immunized 
once with Ad.pIXgp70, and immunized 15  weeks later 
with Ad.TxnGagL. When we analyzed the GagL85–93-spe-
cific CD8+ T cell response two weeks later, control mice 
that had been naïve prior to Ad.TxnGagL immuniza-
tion showed a significant induction of specific CD8+ 
T cells, while the mice that had been pre-immunized 
with Ad.pIXgp70 were still mostly unable to mount a 
GagL85–93-specific CD8+ T cell response (Fig. 2g), clearly 
demonstrating that immunization with an F-MuLV Env 
encoding vector leads to long-term modification of the 
response to a subsequent immunization.
Immunization with envelope encoding adenovirus vectors 
does not lead to expansion of regulatory T cells
As the impact of F-MuLV Env encoding vectors on sub-
sequent immunizations was strong and long-lasting, we 
suspected a potential role for regulatory T cells. There-
fore, we repeated the sequential immunization with 
Ad.pIXgp70 and Ad.TxnGagL and analyzed the fre-
quency of regulatory FoxP3+ CD4+ T cells, as well as 
their activation status, in draining lymph nodes three 
(See figure on next page.) 
Fig. 2 Immune responses and protection induced by sequential Ad-based vaccination. CB6F1 mice were immunized at two time points with 
109 vp of the indicated vaccines; immunizations were performed in a three-week interval, only one vaccine was used in each immunization. The 
GagL85–93-specific CD8
+ T cell response was analyzed by MHC I tetramer staining of peripheral blood cells two weeks after the second immuniza-
tion (a). Three weeks after completion of the immunizations, mice were challenged with FV, and 10 days after FV infection GagL85–93-specific CD8
+ T 
cell responses (b) and Env123–141-specific CD4
+ T cells (c) were analyzed in peripheral blood cells by MHC I and MHC II tetramer staining, respectively. 
FV load in plasma was analyzed 10 days (d), viral load in spleens three weeks after FV infection (e). F-MuLV-binding antibody titers were analyzed in 
sera collected two weeks after completion of the immunizations (f). In another experiment, CB6F1 mice were immunized once with Ad.TxnGagL, 
with or without an immunization with Ad.pIXgp70 three months earlier. GagL85–93-specific CD8
+ T cell responses were analyzed in peripheral blood 
by MHC I tetramer staining two weeks after Ad.TxnGagL immunization (g). The data shown were obtained in two independent experiments (a, d, e) 
or one experiment (b, c, f, g). Each dot represents one mouse, lines indicate mean [a–c, g (grey line: mean value calculated with exclusion of outlier)] 
or median (d–f) values, dashed lines indicate detection limits. Data were analyzed by Kruskall–Wallis One Way Analysis of Variance on Ranks and 
Dunn’s multiple comparison procedure (a–e, g without exclusion of outlier from the calculation), One Way Analysis of Variance and Student–New-
man–Keuls multiple comparison procedure (g with exclusion of outlier from the calculation) or Mann–Whitney Rank Sum Test (f). Significant differ-
ences (P < 0.05) compared to unvaccinated mice are indicated by *, significant differences compared to mice vaccinated with the respective single 
vaccine are indicated by # (a, b: compared to Ad.TxnGagL; F: compared to Ad.pIXgp70); black symbols indicate significant differences calculated 
including all values, grey symbols indicate significant differences after exclusion of the outlier (g). Sufficient statistical power was verified [SP = 0.99 
(a), 0.99 (b), 0.81 (c), 0.99 (d), 0.99 (e), 1.0 (f), 0.99 (g)]
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days after the Ad.TxnGagL immunization. When we 
compared the frequency of regulatory T cells in the CD4+ 
T cell subset (Fig.  3a), there was no significant increase 
in the mice that had been immunized with Ad.pIXgp70 
before the immunization with Ad.TxnGagL compared to 
naïve mice, pre-naïve Ad.TxnGagL immunized mice or 
mice that had been pre-immunized with Ad.GFP. Also 
the activation status of the regulatory CD4+ T cells was 
not significantly altered by any of the immunizations 


















































































































































































Fig. 3 Induction of regulatory T cells by Ad-based vaccination. CB6F1 mice were immunized with 109 vp Ad.TxnGagL, either as a single immuniza-
tion or after pre-immunization with 109 vp Ad.GFP or Ad.pIXgp70. Three days after the Ad.TxnGagL immunization, the frequencies of regulatory 
FoxP3+ CD4+ T cells (a), of CD44+ FoxP3+ CD4+ T cells (b), of CD62Llow FoxP3+ CD4+ T cells (c), and of KLRG1+ FoxP3+ CD4+ T cells (d) were 
analyzed in draining lymph nodes. The data shown were obtained in two independent experiments. Each dot represents one mouse, lines indicate 
mean values. Data were analyzed by Kruskall–Wallis One Way Analysis of Variance on Ranks and Dunn’s multiple comparison procedure, n.s. not 
significant (P > 0.05)
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(Fig. 3b–d). Thus, we did not find any evidence for a con-
tribution of regulatory CD4+ T cells to the immunosup-
pression observed after F-MuLV Env immunization.
Immunization with envelope encoding adenovirus vectors 
leads to higher antibody titers in adenovirus‑experienced 
mice
We followed up on the surprising finding that the mice 
that had received Ad.GFP before the actual immu-
nization with Ad.pIXgp70 mounted higher antibody 
responses, enquiring if the effect would persist if mice 
received a higher dose of control Ad vector before immu-
nization with Ad.pIXgp70 or with the conventional enve-
lope-encoding Ad.Env, using 1010 vp of Ad.empty for the 
pre-treatment. Two weeks after the immunization with 
Ad.pIXgp70 or Ad.Env we analyzed the F-MuLV-binding 
antibody response (see Additional file 4A for the experi-
mental layout); while mice that had received only the 
envelope-encoding vectors had not mounted a significant 
antibody response at the time, those mice that had been 
injected with Ad.empty before the actual immunization 
with Ad.pIXgp70 or Ad.Env had significantly higher anti-
body titers (Fig. 4). To investigate if this effect is limited 
to envelope protein, we performed a similar experiment 
with a leader-gag encoding Ad vector; again, mice that 
had been pre-treated with an empty Ad vector mounted 
significantly higher binding antibodies than pre-naïve 
mice (Additional file 5).
It is widely acknowledged that in pre-immune individu-
als, the presence of anti-adenovirus neutralizing antibod-
ies abrogates the induction of transgene-specific immune 
responses; the induction of anti-vector immunity by 
repeated immunizations also diminishes the induction of 
transgene-specific immunity in vector-based immuniza-
tion (reviewed in [62]). We established a pre-immuniza-
tion protocol using two immunizations with 109 vp of the 
control vector Ad.empty that leads to induction of Ad-
specific CD8+ T cell responses and Ad-specific antibod-
ies (Additional file 6A, B), and results in complete loss of 
induction of transgene-specific CD8+ T cell responses 
to a subsequent immunization with Ad.TxnGagL (Addi-
tional file  6C). Interestingly, when we pre-immunized 
mice in this way and subsequently immunized them 
with Ad.Env, their antibody response was significantly 
higher than after an immunization without prior ade-
novirus injection (Fig.  5a). We also performed cell and 
plasma transfer from pre-immunized mice to naïve mice 
before Ad.Env immunization (see Additional file  4B for 
the experimental layout), but could not demonstrate an 
enhancing effect by either transfer; but as all but one 
mice that had received CD4+ T cells from Ad.empty 
pre-immunized mice had no detectable anti-F-MuLV 
antibody titer, the involvement of CD4+ T cells seems 
unlikely. Importantly, the transfer of Ad-immune plasma 
did not lead to an abrogation of Env-specific antibody 
induction.
To dissect the role of different plasma components, 
we performed another transfer experiment, where 
we addressed the role of neutralizing antibodies and 
cytokines separately. For this, plasma from Ad pre-
immunized mice with high titers of binding antibodies 
was cleared of antibodies by repeated incubation with 
protein G-Sepharose; on the other hand, we used the 
neutralizing hexon-specific antibody 9C12 [63] either at 
a concentration resulting in a titer similar to the whole 
anti-Ad antibody titer found in pre-immunized mice, or 
at a 100-fold reduced concentration, which we found to 
represent the titer of neutralizing antibodies in plasma 
samples from pre-immunized mice (data not shown). 
We analyzed the binding antibody titers two weeks after 
one (Fig. 5b) or two immunizations (Fig. 5c) with Ad.Env, 
and found no significant differences between the groups, 
importantly including the mice that were treated with the 
neutralizing 9C12 antibody, indicating that priming of 
the antibody response was not impaired by the presence 






























Fig. 4 Env-specific binding antibodies after Ad-based vaccination of 
Ad-experienced mice. CB6F1 mice were immunized with 109 vp of 
the indicated envelope vaccines, with or without immunization with 
1010 vp Ad.empty three weeks prior as indicated. F-MuLV-binding 
antibody titers were analyzed two weeks after completion of the 
immunization. The data shown were obtained in two independent 
experiments, using 2–4 mice per group per experiment. Each dot rep-
resents one mouse, lines indicate median values, dashed lines indicate 
the limit of detection. Data were analyzed by Mann–Whitney Rank 
Sum Test. Significant differences (P < 0.05) compared to mice vac-
cinated only with the envelope vaccine are indicated by #. Sufficient 
statistical power was verified (SP = 0.99)



































































































































































































































































Fig. 5 Influence of pre-existing immunity on Ad-based induction of Env-specific binding antibodies and CD4+ T cells. CB6F1 mice were immu-
nized with Ad.Env without pre-treatment, three weeks after two pre-immunizations with 109 vp Ad.empty in three-week intervals, or one day after 
transfer of 107 CD4+ T cells, or 200 µl plasma, or both from Ad pre-immune mice. Binding antibodies were analyzed two weeks after immunization 
with Ad.Env (a). In another transfer experiment, mice received plasma or antibody-cleared plasma from Ad pre-immune mice, or the Ad-neutral-
izing antibody 9C12 before immunization with 109 vp Ad.Env. Binding antibodies were analyzed two weeks after one (b) or two immunizations 
with Ad.Env (c). Two weeks after the first Ad.Env immunization, blood cells were stimulated with Env-derived peptides and cytokine production by 
CD4+ T cells was analyzed by flow cytometry (d). Three weeks after the second Ad.Env immunization, mice were infected with FV and three days 
later, Env123–141-specific CD4
+ T cells were analyzed by MHC II tetramer staining (e). The data shown were obtained in two or three (b: Ad.Env and 
Ad-plasma,Ad.Env) independent experiments with four mice per group. Each dot represents one mouse (a–c, e) or mean values (d), lines indicate 
median (a–c) or mean (e) values, dashed lines indicate the limits of detection. Axes of the radar charts all have the scale as indicated for the first axis; 
the order of data shown in all plots is as indicated for the first radar chart (d). Data were analyzed by Kruskall–Wallis One Way Analysis of Variance on 
Ranks and Dunn’s multiple comparison procedure. Significant differences (P < 0.05) compared to unvaccinated mice are indicated by *, significant 
differences compared to mice vaccinated with Ad.Env are indicated by #. Sufficient statistical power was verified [SP = 0.99 (a), 1.0 (b), 1.0 (c), 0.93 
(d: IFNγ), 0.99 (e)]
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equally efficient in all groups. When we analyzed the 
cytokine production by Env-specific CD4+ T cells after 
the first Ad.Env immunization, we found that the mice 
immunized with Ad.Env produced IFNγ, slightly less 
IL10 and low levels of interleukins 2, 4 and 21 (Fig. 5d). 
The induction of cytokine-producing cells was not sig-
nificantly changed by transfer of Ad-immune plasma 
prior to Ad.Env immunization, and slightly enhanced 
when antibody-cleared plasma was transferred. Trans-
fer of the neutralizing antibody 9C12 resulted in a slight 
trend to lower cytokine production levels, which was 
also observed when a low dose of 9C12 was transferred. 
We also analyzed the frequency of Env-specific CD4+ 
T cells by MHC II tetramer staining three days after FV 
challenge infection, and found a significant induction 
of Env-specific CD4+ T cells in mice immunized with 
Ad.Env without pre-treatment as well as in mice that had 
received antibody-cleared plasma or a low dose of the 
neutralizing antibody 9C12 before Ad.Env immunization, 
and the frequency was only slightly reduced in mice that 
had received adenovirus-immune plasma or a high dose 
of the adenovirus-neutralizing antibody (Fig. 5e).
Overall, our results demonstrate that neither the 
induction of antibodies nor of CD4+ T cells is severely 
impacted by transfer of either pre-immune serum, 
the cytokines contained therein, or Ad-neutralizing 
antibodies.
Combining adenovirus‑based vaccines to induce strong 
protection against high‑dose Friend virus infection
We learned from our experiments that we have to 
immunize mice with the CD8+ T cell inducing vaccine 
first, before immunizing with Env encoding vectors, in 
order to elicit the full width of immune responses that 
the individual vaccines are capable of inducing. There-
fore we developed a sequential vaccination protocol that 
encompasses one immunization with Ad5.TxnGagL and 
Ad5.GagC1K, reasoning that the combination of the two 
vaccines would induce strong GagL85–93-specific CD8+ 
T cell as well as Gag-specific CD4+ T cell responses, fol-
lowed by one immunization with Ad5.pIXgp70, which 
should result in appreciable antibody levels after a sin-
gle immunization in the Ad5-experienced mice. We 
performed this experiment side-by-side with an immu-
nization with attenuated helper virus F-MuLV-N. This 
N-tropic F-MuLV is highly attenuated in the CB6F1 
mice (Fv1b/b) employed in our immunization studies 
and has been described to confer complete protection 
from a subsequent challenge infection even in highly 
susceptible mice [10, 16, 32] and can therefore be con-
sidered as the gold standard that a vector-based immu-
nization has to meet.
When we analyzed the immune response to our 
vaccination regimens one week before the FV chal-
lenge infection, we confirmed the strong induction of 
GagL85–93-specific CD8+ T cells by our Ad-based vac-
cine (Fig.  6a), and a slight induction of Env123–144-spe-
cific CD4+ T cells (Fig. 6b); interestingly, there were no 
significant levels of either GagL85–93-specific CD8+ or 
Env123–144-specific CD4+ T cell responses in F-MuLV-
N immunized mice. When we analyzed the F-MuLV-
binding antibody titers on the other hand, mice that 
had been immunized with F-MuLV-N had significantly 
higher binding antibody levels than Ad immunized mice 
(Fig. 6c), and exhibited substantial neutralizing antibody 
levels before challenge infection (Fig. 6d left panel). After 
the FV challenge infection, also the Ad5 immunized 
mice mounted a robust neutralizing antibody response, 
indicating efficient priming by the vaccine (Fig. 6d, right 
panel). Even though the immune responses in the two 
immunization groups differed remarkably, all immunized 
mice were able to tightly control a high dose FV challenge 
infection, with undetectable viral loads in plasma on day 
10 in all but one F-MuLV-N-immunized mice (Fig.  6e) 
and very low or undetectable viral loads in spleens on day 
21 after FV challenge (Fig. 6f ).
(See figure on next page.) 
Fig. 6 Comparison of immune responses and protection induced by a combined Ad-based vaccine and the attenuated retrovirus F-MuLV-N. CB6F1 
mice were either immunized with an Ad based vaccine, consisting of an immunization with 109 vp each of Ad.TxnGagL and Ad.GagC1K, followed by 
an immunization three weeks later with 109 vp Ad.pIXgp70, or mice were immunized with 10 000 FFU of the N-tropic F-MuLV-N. 6 weeks after the 
first immunization, mice were challenged with 5000 SFFU FV complex. The frequencies of GagL85–93-specific CD8
+ T cells (a) and Env123–141-specific 
CD4+ T cells (b) were analyzed by MHC I and MHC II tetramer staining, respectively, five weeks after initialization of the immunizations (i.e. 2 weeks 
after Ad.pIXgp70 immunization); the binding antibody response was analyzed at the same time point (c). Neutralizing antibodies were quantified 
both five weeks after initialization of the immunizations (d, left) and 10 days after the FV challenge infection (d, right). The viral load in plasma was 
analyzed 10 days after FV challenge infection (e), the viral load in spleens was analyzed three weeks after the FV challenge infection (f). The data 
shown were acquired in three (b–d) to five independent experiments (a, e, f) using three to five mice per group per experiment. Each dot repre-
sents one mouse, lines indicate mean (a, b) or median (c–f) values, dashed lines indicate the limits of detection. Data were analyzed by Kruskall–Wal-
lis One Way Analysis of Variance on Ranks and Dunn’s multiple comparison procedure (a, b, d–f) or by Mann–Whitney Rank Sum Test (c). Significant 
differences (P < 0.05) compared to unvaccinated mice are indicated by *, significant differences compared to mice vaccinated with the Ad-based 
vaccine are indicated by #. Sufficient statistical power was verified [SP = 0.99 (a), 0.88 (b), 1.0 (c), 0.99 (d left), 1.0 (d right), 0.99 (e), 0.99 (f)]
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Discussion
Our data clearly demonstrate the potency of an adeno-
virus-based immunization that confers strong protec-
tion from FV infection in highly susceptible mice, and 
highlight the important role of immunogen interference 
effects. The finding that the F-MuLV envelope exerts 
a potent suppression on the immune response to other 
immunogens is very intriguing, and the underlying 
mechanism is still unclear. Retroviral envelope proteins 
are known to contain an immunosuppressive domain in 
the transmembrane envelope subunit that is conserved 
across a wide range of exogenous and endogenous retro-
viruses (reviewed in [64]), and it has been suggested that 
altered cytokine expression profiles, including upregu-
lated levels of IL6 and IL10 but also decreased levels of 
IL2, underlie the suppressive effect [65]. In our experi-
ments, we could demonstrate IL10 production also by 
Env-specific CD4+ T cells. However, the immunosup-
pressive domain is located in the transmembrane enve-
lope protein, whereas the suppressive activity observed 
in our experiments was also exerted by gp70, i.e. the 
surface envelope protein, alone. There have been few 
publications until now that report a similar effect in 
DNA immunizations in mice or macaques; it was dem-
onstrated that HIV Env gp120, but not SIV Env gp130 or 
EIAV Env gp90, abrogated CD8+ T cell responses to HIV 
Gag gp55 [66], others found similar effects for HIV Env 
and Gag and showed that a reduction of the Env plas-
mid [67], spatial separation of the Env and Gag plasmids 
or mutation of an Env epitope [68] led to the rescue of 
Gag-specific CD8+ T cell induction, suggesting epitope 
competition as an underlying mechanism. Others found 
a reduction of HIV-specific CD8+ T cell responses only 
when the vectored vaccine was combined with an adju-
vanted env gp120 protein vaccine, but not when the vac-
cine was combined with a vectored gp120 vaccine, but 
it is unclear if this effect was mediated by env gp120 or 
the adjuvant [69]. It seems unlikely that epitope compe-
tition is the cause for the immunosuppression described 
here for F-MuLV Env; while we cannot exclude the pres-
ence of any CD8+ T cell epitopes in F-MuLV Env, the 
only known CD8+ T cell epitope of FV is the H-2Db 
restricted GagL85–93 epitope [58], and while new CD4+ 
T cell epitopes were described recently [60], numerous 
attempts by us and other groups, using spleen cells from 
FV-infected mice or from mice immunized with Ad- or 
plasmid DNA-based vectors, have failed to identify any 
further epitopes (unpublished data). Ad5 capsid proteins 
are very immunogenic and can have an adjuvant effect on 
encoded transgenes or co-delivered substances [70–73], 
but the Ad5 proteins also contain CD8+ T cell epitopes 
that compete with transgene-derived epitopes [74, 75], 
therefore the emergence of subdominant epitopes from 
proteins when expressed from Ad5 vectors seems rather 
unlikely. Furthermore, spatial separation of the Env and 
Gag vaccines did not rescue GagL85–93-specific CD8+ T 
cell induction, and the suppressive effect was maintained 
when the Env immunization preceded the Gag immuni-
zation, even by as much as three months. While the last-
ing suppression of CD8+ T cell responses to a subsequent 
immunization suggests an adaptive process, we did not 
find a significant expansion or activation of regulatory T 
cells or an altered induction of adenovirus-specific anti-
bodies (data not shown) upon immunization with an 
envelope-encoding vector compared to other adenovirus 
vectors. The immediacy of the suppressive effect, which 
is not relieved by spatial separation, suggests a systemic 
mechanism like altered cytokine levels; as its lasting 
nature argues for an adaptive process, our findings may 
imply a role of cytokine producing cells of the adaptive 
immune system. It has been shown that the induction of 
immune responses by adenovirus-based vaccines relies 
on CD4+ T cell help [76–78]; furthermore, HIV gp120 
immunization was demonstrated to introduce a Th2 bias 
via the stimulation of IL10 [79]; thus, a skewed helper T 
cell profile might underlie the suppression of CD8+ T cell 
induction by a subsequent adenovirus-based immuniza-
tion. Our findings could have wider implications if they 
would apply to retroviral envelope proteins in general, 
and therefore warrant further investigation, both with 
regard to the mechanism and to their transferability.
To our knowledge, this is the first report on enhanced 
antibody responses to adenovirus-delivered immuno-
gens in adenovirus-experienced recipients. It is widely 
accepted that pre-existing anti-adenovirus immunity 
leads to a loss of efficacy of adenovirus-based vaccines 
(reviewed in [80]). In many studies however, the focus 
of the analyses was on cellular immune responses; when 
antibody responses were analyzed, some studies showed 
no influence of pre-immunization on the induction of 
transgene-specific antibody responses by adenovirus-
based immunization [81], while other studies reported 
a reduction or even complete abrogation of transgene-
specific immune responses, including antibody responses 
[82, 83]. Differences in the effects observed here and in 
other studies may be due to different levels of anti-ade-
novirus immunity; however, also in our experiments we 
worked with a pre-immunization schedule that would 
abrogate induction of transgene-specific CD8+ T cells by 
a subsequent adenovirus-based immunization, indicat-
ing that mice had mounted a relevant level of adenovi-
rus-specific immunity. It has been reported for bacterial 
vector based immunization that a pre-existing immunity 
against the vector can lead to improved transgene-spe-
cific antibody responses (reviewed in [84]). In a study of 
a Salmonella enterica-based vaccine, the authors found 
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improved immune responses in pre-immune mice, and 
attributed the enhanced efficacy to an antibody-facili-
tated uptake by macrophages [85]. While our transfer 
experiments did not clarify the mechanism underlying 
the enhanced antibody levels in adenovirus-experienced 
mice, they did show that adenovirus-specific antibod-
ies in particular did not have an abrogating effect on the 
adenovirus-based immunization, as might be expected. 
Analyzing the contribution of isolated components of 
the immune response may not be a feasible approach to 
fully grasp the complexity of the immune response in an 
adenovirus-experienced recipient, and further research is 
needed to understand the immune enhancement in ade-
novirus-experienced mice that we describe here.
When we combined our adenovirus based Env and 
Gag vaccines, we could show that in spite of the lack of 
GagL85–93-specific CD8+ T cell responses, mice were 
fairly strongly protected from the high dose FV challenge, 
which is well in line with our previous data [27]; here 
the protection is probably mainly antibody-mediated, 
although we cannot exclude the presence of unknown 
CD8+ T cell epitopes. We demonstrated very strong 
protection from FV challenge infection and FV-induced 
disease in immunized mice when the vaccines were 
administered sequentially; interestingly, the immune 
responses significantly differed from those induced by 
the live-attenuated vaccine virus F-MuLV-N in strength 
and quality, with no detectable GagL85–93-specific CD8+ 
T cell response to F-MuLV-N but a superior antibody 
response compared to the adenovirus-based vaccine 
(summarized in Fig.  7). Our finding that F-MuLV-N 
induced only marginal T cell responses suggests that the 
potent neutralizing antibody response is the main fac-
tor that confers protection, and while it has been dem-
onstrated before in transfer experiments that complex 
immune responses are required for complete protection 
[10], and that depletion of T cells from immunized mice 
would abrogate rapid protection from FV challenge infec-
tion [86], it could also be demonstrated that the presence 
of neutralizing antibodies at the time of challenge infec-
tion is crucial for sterile protection [33]. The adenovirus-
based vaccine on the other hand induced very strong 
GagL85–93-specific CD8+ T cells in immunized mice, 
whereas the antibody response before challenge infec-
tion was fairly low. We saw a rapid increase in neutral-
izing antibodies after FV challenge infection which was 
probably assisted by the vaccine-induced CD4+ T cells, 
but it has to be assumed that the lack of potent neutrali-
zation prior to FV challenge infection prevents complete 
protection. An advantage of attenuated virus-based vac-
cines is the high identity with the pathogen against which 
they are supposed to protect, which holds true also here, 
as the N-tropic and B-tropic F-MuLV differ only in a 
few amino acids in the sequence of the capsid protein 
[87–89]. It is known that retroviral envelope proteins 
are extensively and intricately glycosylated [90], which is 
challenging for vaccine design, as incorrect glycosylation 
patterns, which are likely to occur in a gene-based vac-
cine but not in the attenuated virus which is replicating 
at low level in vivo, can lead to the induction of irrelevant 
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Fig. 7 Summary of the immunization experiments with the combined Ad-based vaccine and F-MuLV-N. The radar chart represents the results from 
Fig. 6, showing (clockwise from the top) the mean percentage of GagL85–93-specific CD8
+ T cells (MHC I Tet+ CD44+/CD8+), the mean percentage of 
Env123–141-specific CD4
+ T cells (MHC II Tet+ CD44+/CD4+), the mean log10 binding antibody titer, the mean log2 neutralizing antibody titer before, 
and after, FV challenge infection, and the median viral loads in plasma on day 10, and in spleens on day 21 after FV challenge infection
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Numerous different strategies have been employed in 
the FV model to date, including attenuated F-MuLV or 
FV [10, 16, 32, 94], replication-defective [34] or inacti-
vated virus [35], protein- and peptide-based vaccines 
[36–39, 42], cell-based vaccines, and gene-based vaccines 
such as plasmid DNA-based [43], vaccinia virus-based 
[44, 46] or adenovirus-based vaccines [26–31]. While 
comparisons of all these vaccine approaches are com-
plicated by the use of different mouse strains and widely 
differing FV challenge doses, it can be determined from 
these studies that the vaccines that conferred strong 
protection from FV challenge are the attenuated viruses 
[10, 16, 32, 94], inactivated virus delivered with complete 
Freund’s adjuvant [35], a peptide-based vaccine deliv-
ering F-MuLV-derived peptides in calcium phosphate 
nanoparticles together with CpG-containing oligodeoxy-
nucleotides as adjuvant [42], and viral vector based vac-
cines such as an envelope-encoding vaccinia virus [46] 
or some of the adenovirus-based vectors developed by 
us [27, 30, 31]. Interestingly, some of these experiments 
demonstrate that strong protection from FV challenge is 
indeed possible without significant induction of neutral-
izing antibodies, which were reported to be undetectable 
[46] or at very low level before the FV challenge infec-
tion [27, 30] or not induced by the vaccine by design 
[31, 42, 44], and also demonstrated an important role of 
non-neutralizing binding antibodies [33]. The only vac-
cine for which complete protection with absence of any 
virus-producing cells was demonstrated [16], and for 
which we found robust neutralizing antibody responses 
after immunization in the experiments shown here, is the 
attenuated F-MuLV-N. The protection observed in our 
mouse model in the highly susceptible CB6F1 mice was 
not actually complete as described for other susceptible 
hybrid mouse strains, but this is probably attributable to 
the very high susceptibility to FV-induced disease of the 
CB6F1 mice and the high challenge dose employed in our 
experiments, and emphasizes the stringency of our chal-
lenge model.
Conclusions
We demonstrate here an adenovirus-based vaccination 
approach that mediates robust protection from retrovi-
rus infection in a highly stringent mouse infection model 
and is comparable in its efficacy to a live-attenuated ret-
rovirus vaccine, although the mechanisms of protection 
clearly differ. Our results highlight that the order of vac-
cine delivery is important for the immunization out-
come as a retroviral surface envelope protein can exert 
suppressive effects on simultaneously or subsequently 
administered immunogens, and pre-existing immunity in 
Ad-experienced recipients can actually lead to improved 
transgene-specific antibody responses.
Additional files
Additional file 1. Suppression of OT-I specific CD8+ T cells by F-MuLV 
Env. CB6F1 mice were immunized once with 109 vp Ad.ova, or with Ad.ova 
in combination with Ad.env. To ensure that mice of both groups were 
inoculated with an equal amount of viral particles, the Ad.ova group 
received an additional 109 vp of an empty Ad vector. The ovalbumin-spe-
cific CD8+ T cell response was analyzed by intracellular cytokine staining 
after in vitro restimulation of peripheral blood cells two weeks after the 
immunization. The production of IFNγ by ova257–264-peptide restimulated 
CD8+ T cells was significantly lower in mice co-immunized with Ad.env. 
The data shown were obtained in two independent experiments, each 
dot represents an individual mouse. Black lines indicate the mean values, 
the grey line indicates the mean value after outlier exclusion. Data were 
analyzed for statistically significant difference, # indicates P < 0.05. Statisti-
cal significance was calculated with and without inclusion of the outlier 
and was confirmed for both cases (black symbol: inclusion of outlier, 
Mann–Whitney Rank Sum Test, P = 0.002; grey symbol: exclusion of 
outlier, t-test, P = 0.002).
Additional file 2. Experimental layout. CB6F1 mice were immunized with 
109 vp of Ad.pIXgp70 or Ad.TxnGagL, or Ad.GFP as a control, in week 0, 
followed by a second immunization in week 3 with 109 vp of Ad.pIXgp70 
or Ad.TxnGagL as indicated. Antibody responses and CD4+ and CD8+ T 
cell responses were analyzed at the indicated time points. In week 6, mice 
were challenged with 5000 SFFU FV, and plasma and spleen viral loads 
were analyzed at the indicated time points.
Additional file 3. Cytokine production by GagL85–93-specific CD8
+ T 
cells after sequential immunization. CB6F1 mice were immunized at two 
time points with 109 vp of the indicated vectors; immunizations were 
performed in a three-week interval, only one vector was used in each 
immunization. The GagL85–93-specific CD8
+ T cell response was analyzed 
two weeks after the second immunization by intracellular cytokine stain-
ing after restimulation with GagL85–93 peptide. The pie charts indicate 
the mean frequency of CD44+ CD8+ T cells producing multiple or single 
cytokines, the arcs around the pies indicate production of the cytokines 
IFNγ, TNFα and IL2. The size of the pie charts indicates the total frequency 
of cytokine producing CD44+ CD8+ T cells, which is also stated below 
the group names (% cytokine-producing CD44+ of CD8+ cells). Mean 
values were calculated from data of 3 mice per group; data were analyzed 
for statistically significant differences by One Way ANOVA on Ranks and 
Student–Newman–Keuls post testing, * indicates P < 0.05 compared to 
unvaccinated mice.
Additional file 4. Experimental layout. (A) CB6F1 mice were immunized 
with 109 vp of Ad.pIXgp70 or Ad.Env in week 3, with or without a pre-
immunization with an empty Ad vector in week 0. Antibody responses 
were analyzed in week 5. (B) CB6F1 mice were immunized twice with 109 
vp of Ad.empty, one group of mice was immunized with 109 vp of Ad.env 
in week 6 (upper panel), another group of mice was sacrificed at this 
time point to collect plasma and CD4+ T cells that were transferred either 
seperately or as an admixture into naïve recipient CB6F1 mice, which were 
immunized one day later with 109 vp of Ad.Env (lower panel). Antibody 
responses were analyzed in week 8 (week 2* for transfer recipient mice).
Additional file 5. Enhanced binding antibody titers after Ad.leader-gag 
immunization of Ad pre-immune mice. CB6F1 mice were pre-immunized 
twice in a three-week interval with 109 vp Ad.empty, and immunized 
three weeks later with 109 vp Ad.leader-gag, a control group received only 
the injection of the vaccine vector Ad.leader-gag without pre-immuniza-
tion. The F-MuLV-binding antibody titers were analyzed in blood samples 
collected two weeks after the Ad.leader-gag immunization by ELISA. Mice 
that had been pre-immunized showed significantly higher binding anti-
body levels than pre-naive mice. Each dot represents an individual mouse, 
the lines indicate the median values. Data were analyzed for a statisti-
cally significant difference by Mann–Whitney Rank Sum Test, # indicates 
P < 0.05. Sufficient statistical power was verified (SP = 0.95).
Additional file 6. Repeated Ad pre-immunization leads to unrespon-
siveness to Ad.TxnGagL immunization. CB6F1 mice were pre-immunized 
twice in a three-week interval with 109 vp Ad.empty, and immunized 
three weeks later with 109 vp Ad.TxnGagL, a control group received only 
the injection of the vaccine vector Ad.TxnGagL without pre-immunization. 
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